RT @pinacol: 中等度の腎機能障害(eCrCl=31-50)においてオラパリブの曝露は44%増加することから、注意深くモニタリングし、投与量を1回200mg1日2回へ調整すべきである。 https://t.co/W0HdC8G1Fq
Rolfo, C.-Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Imp... https://t.co/qqbhqqgf4I
中等度の腎機能障害(eCrCl=31-50)においてオラパリブの曝露は44%増加することから、注意深くモニタリングし、投与量を1回200mg1日2回へ調整すべきである。 https://t.co/W0HdC8G1Fq
RT @ChristianRolfo: Today online! Our phase I paper on Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and…
RT @ChristianRolfo: Today online! Our phase I paper on Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and…
RT @ChristianRolfo: Today online! Our phase I paper on Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and…
RT @ChristianRolfo: Today online! Our phase I paper on Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and…
RT @ChristianRolfo: Today online! Our phase I paper on Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and…
RT @ChristianRolfo: Today online! Our phase I paper on Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and…
RT @ChristianRolfo: Today online! Our phase I paper on Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and…
RT @ChristianRolfo: Today online! Our phase I paper on Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and…
RT @ChristianRolfo: Today online! Our phase I paper on Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and…
RT @ChristianRolfo: Today online! Our phase I paper on Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and…
RT @ChristianRolfo: Today online! Our phase I paper on Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and…
RT @ChristianRolfo: Today online! Our phase I paper on Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and…
Today online! Our phase I paper on Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment | Springer Nature Link @SpringerNature https://t.co/NUUEQx5DXz